U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines - 08/16/2022
  1. News & Events for Human Drugs


Event Title
Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines
August 16 - 18, 2022

August 16 - 18, 2022
- ET
- ET
- ET


Visit CDER Small Business and Industry Assistance Page


Janet Woodcock, MD

Janet Woodcock, M.D.
Principal Deputy Commissioner - Office Of The Commissioner
U.S. Food and Drug Administration (FDA)


CDER SBIA is hosting this three half-days conference in collaboration with the Promoting the Quality of Medicines Plus (PQM+) program, which is funded by the U.S. Agency for International Development (USAID) and led by the United States Pharmacopeial Convention. PQM+ provides technical assistance to build in-country capacity of medical products regulatory authorities’ QA systems in low-and middle-income countries (LMICs). PQM+ also provides technical support to manufacturers of quality-assured priority medical products for tuberculosis (TB), malaria, neglected tropical diseases, other infectious diseases, and family planning and reproductive health as well as maternal, newborn, and child health.

This event is intended to help National Medicines Regulatory Authority's (NMRA) in low-and middle-income countries (LMICs) gain a better understanding of the following:

  • FDA's role in international regulatory harmonization.
  • How FDA interacts with the World Health Organization (WHO) and NMRAs to support the process for approving drugs in LMICs.
  • USP and USAID’s PQM+ program’s role in supporting of strengthening regulatory systems in LMICs.
  • Regulatory resources available to NMRAs in LMICs.


  • International Regulatory Harmonization
  • FDA International Collaborations, including WHO
  • FDA drug approval pathways and FDA review of drug applications (new and generic drugs). Specific emphasis will be made on approval pathways for new TB medicines.
  • FDA review of stability testing, bioequivalence and post-marketing changes
  • Nitrosamines Impurities
  • USP and USAID’s PQM+ capabilities for strengthening regulatory systems in LMIC.


  • Global regulators, particularly those from low- and middle-income countries (LMICs)
  • Regulatory science and regulatory affairs professionals, industry, consultants, or contractors who are involved with:
    • The submission of INDs, NDAs, BLAs and ANDAs
    • New and generic drug development
    • Generic drug bioequivalence, stability, biowaivers and dissolution
  • Global public health programs supporting access to quality-assured medicines



Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.

This course has been:

  • pre-approved by RAPS as eligible for a maximum of 12 credits for a two day event (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.
  • pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
  • pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.
  • approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.


  • To optimize your webinar experience, use Chrome when viewing Adobe Connect in a browser.
  • Please contact info@sbiaevents.com for all technical questions.
  • If you encounter any technical issues before or during the event, please visit the Technical Issues Support.
  • Test your PC for use with Adobe Connect prior to the day of the event. Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.



Back to Top